{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    15,
    35,
    36,
    39,
    40,
    43
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Reference to Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9, Study Assessments and Procedures, to Section 2 for the timing of study procedures."
      },
      {
        "id": "ref_2",
        "name": "Reference to Clinical Laboratory Tests Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 9, Study Assessments and Procedures, to Appendix 2 for a list of laboratory tests."
      },
      {
        "id": "ref_3",
        "name": "Reference to Blood Sampling Summary Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Blood Sampling Summary",
        "description": "Reference from Section 9, Study Assessments and Procedures, to Appendix 5 for a summary of invasive samples."
      },
      {
        "id": "ref_4",
        "name": "Reference to Edinburgh Hypoglycemia Scale",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Edinburgh Hypoglycemia Scale",
        "description": "Reference from Section 9.1.3, Exploratory Efficacy Assessments, to Appendix 7 for the self-reported assessment tool."
      },
      {
        "id": "ref_5",
        "name": "Reference to Treatment Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Treatment",
        "description": "Reference from Section 9.2.2, Glucagon Administration, to Section 7 for details regarding treatments."
      },
      {
        "id": "ref_6",
        "name": "Reference to Nasal and Non-nasal Score Questionnaire",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
        "description": "Reference from Section 9.2.2.1, Nasal LY900018 Administration, to Appendix 6 for the questionnaire to be used if a patient sneezes."
      },
      {
        "id": "ref_7",
        "name": "Reference to Hepatic Monitoring Tests",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
        "description": "Reference from Section 9.5.5.2, Hepatic Safety, to Appendix 4 for the list of liver tests to be repeated in case of abnormalities."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 16
      },
      {
        "id": "annot_3",
        "text": "Pregnancy (maternal or paternal exposure to investigational product) does not meet the definition of an AE. However, to fulfill regulatory requirements any pregnancy should be reported following the SAE process to collect data on the outcome for both mother and fetus.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3.1. Serious Adverse Events",
        "pageNumber": 40
      },
      {
        "id": "annot_4",
        "text": "Only severe hypoglycemic episodes will be reported separately as AEs. If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious in the CRF (that is, recorded as an SAE).",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.5.5.1. Hypoglycemic Event Reporting",
        "pageNumber": 44
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "I8R-JE-IGBJ(a)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-12-05",
        "description": "Protocol Amendment (a) to base protocol I8R-JE-IGBJ. Base protocol approved 26 October 2017.",
        "amendmentNumber": "Amendment (a)"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 4,
      "versionCount": 1
    }
  }
}